Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
full phase 3 results will be out in 2016 but we can expect interim results later this year .
BLUSF-DD ..A FANTASTIC INVESTMENT TO MAKE BIG MONEY !!!
Just look at Volume and you will know that almost nobody knows this Monster Sleeping Giant with brutally upside potential means you have the opportunity to buy at the Bottom and before it hit the radar of investors .
Here is Why i like the Company so much :
1) Trading at Cash Level
2) Very Low Burn-Rate of $900k per Q (Cash untill Late 2017)
3) Strong Insider and Institutional Ownership (Holding 70% of the 47.3 M Share Outstanding )
4) KIACTA™ for AA Amyloidosis has Orphan Drug Status (NO approved Drugs for this Indication)
5) Previous Phase 3 of KIACTA™ was Successful and they just need the same results in the ongoing Phase 3 to get Approval
6) Great CEO who sold another Company for $4 B to Shire
Bellus Health (BLU.TO) (BLUSF)
Market Cap: $17.6 M
Cash: $16.3 M
Price: $0.41
Shares Outstanding: 47.4 M ( 70% of these Shares held by Insiders and Institutions)
New Slide Presentation ( Jan 2014)
http://www.bellushealth.com/files/doc_presentations/Bellus%20Corporate%20Presentation%20January%202014%20vFINAL.pdf
Interview with Ceo (November 2013)
http://watch.bnn.ca/#clip1047918
Interview
http://www.pharmaboardroom.com/article/interview-roberto-bellini-president-ceo-bellus-health-canada
BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.
The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).
In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.
-
Some key reasons to consider investing in BELLUS Health include:
Focus on rare diseases – pipeline of rare disease projects in areas of high unmet medical need
Late stage pipeline – global Phase III study for KIACTA™ currently enrolling patients
Fully funded business plan – strong balance sheet with cash runway that will meet funding requirements beyond 2017
Key shareholders –shareholder base with proven track record of building successful healthcare companies
----------------------------------------------------
KIACTA™ peak annual revenues projected at $500 million (Summary)
Strong Clinical Results in First Phase III Study
Landmark study in AA amyloidosis: 183 patients treated for 2 years
Important benefits for patients on drug:
Statistically significant reduction in number and risk of reaching
worsening kidney event
Important delay in reaching dialysis New England Journal of
Medicine publication concludes that KIACTA TM slows decline of renal function in AA amyloidosis
MARKET SIZE
Orphan drug designation granted with market protection in the U.S. (7years), Europe and Japan (10 years)
Formulation (Dosing Schedule) and Methods for Treating Amyloidosis with expiry in 2026 5 year patent extension can be applied to provide protection until 2031
MARKET PROTECTION
KIACTA™ peak annual revenues projected at $500 million Clear pharmacoeconomic
rationale due to high cost of kidney disease Premium pricing for comparative rare disease drugs
PARTNERSHIP
Partnership to fund Phase III Confirmatory Study with significant upside for BELLUS shareholders
With global fund Auven Therapeutics, a private equity group specialized in drug development project
financing Auven Therapeutics funding 100% of KIACTA™’s Phase III Confirmatory Study
FINANCIALS
US$10M in upfront by Auven Therapeutics
US$50M in investments by Auven Therapeutics
Proceeds of exit expected to be shared 50-50
BLUSF = Real Undiscovered stock with Monster Upside Potential !
Just look at Volume and you will know that almost nobody knows this Monster Sleeping Giant with brutally upside potential means you have the opportunity to buy at the Bottom and before it hit the radar of investors .
Here is Why i like the Company so much :
1) Trading at Cash Level
2) Very Low Burn-Rate of $900k per Q (Cash untill Late 2017)
3) Strong Insider and Institutional Ownership (Holding 70% of the 47.3 M Share Outstanding )
4) KIACTA™ for AA Amyloidosis has Orphan Drug Status (NO approved Drugs for this Indication)
5) Previous Phase 3 of KIACTA™ was Successful and they just need the same results in the ongoing Phase 3 to get Approval
6) Great CEO who sold another Company for $4 B to Shire
Bellus Health (BLU.TO) (BLUSF)
Market Cap: $17.6 M
Cash: $16.3 M
Price: $0.41
Shares Outstanding: 47.4 M ( 70% of these Shares held by Insiders and Institutions)
New Slide Presentation ( Jan 2014)
http://www.bellushealth.com/files/doc_presentations/Bellus%20Corporate%20Presentation%20January%202014%20vFINAL.pdf
Interview with Ceo (November 2013)
http://watch.bnn.ca/#clip1047918
BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.
The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).
In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.
-
Some key reasons to consider investing in BELLUS Health include:
Focus on rare diseases – pipeline of rare disease projects in areas of high unmet medical need
Late stage pipeline – global Phase III study for KIACTA™ currently enrolling patients
Fully funded business plan – strong balance sheet with cash runway that will meet funding requirements beyond 2017
Key shareholders –shareholder base with proven track record of building successful healthcare companies
first it was not an NDA it was a ANDA and second ANDA´s dont have PDUFA date
IGXT at 0.94 ..load up before she breaks the $1 mark at this level the jumps will be bigger .
FDA DECISION ON FEB 3 .. Market Cap OF $60 Mis still a big joke
IGXT ( Mcap $56 M) RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
FDA DECISION ON FEB 3 ...TGT $2-3
This Super Goldmine and a Once in a Lifetime Opp is just 50 pennies away from all time low . Buying IGXT at this level is like buying ACAD at $1+ or like DNDN at $3 before Exploding to $50++ .
Most people like to buy at the top instead at the bottom .
IGXT (Price 0.82) $2++ possible before FDA decision
IGXT exploding guys
me will hold through Decision but with half of my shares .
IGXT = RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
FDA DECISION ON FEB 3 ..GLTA
IGXT = BREAKOUT IMMINENT GUYS
FDA DECISION ON FEB 3
IGXT (MC $50 M ) is very close to a Major Breakout guys . FDA DECISION ON FEBRUARY 3 . GL
chemist please put that pipeline chart on the box above .thanks
http://intelgenx.com/_assets/images/productpipeline-2014.jpg
IGXT = FDA DECISION ON FEBRUARY 3 =500%++ Potential !!!
IGXT is one of the Best and Most Undervalued Gem in the Biotech Sector . Market Cap of $48 M for a Company with10 Drugs in Late Stage which all could be on the Market within 3 years is more than Ridiculous .
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 35 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $48 M
Cash: $6 M
Price:0.70
Burn-Rate : $2 M a year
Shares Out : 69 M ( 31 M shares are held by Investors )
Mega Product Pipeline
http://intelgenx.com/pipeline/chart.html
New Presentation
http://intelgenx.com/investors/presentations.html
Here is a Summary from he largest Shareholder of IGXT (he sees Tgt of $5-10) !!!
Frankly, my target (first stated in July, 2011) of realizing $3-$8/share from IntelGenx over the
life of the BIPES Fund has never seemed more reason able—the company has put in place more
than enough building blocks to see that kind of sto ck price by the of 2016, as it becomes
recognized as a world leader in the growing area of thin-film drug delivery and development. I
like the fact that my $3 low end corresponds to the already-existing 1-year target of Ram
Selvaraju, a well-respected and sophisticated Wall Street biotech analyst. If the PAR
partnership blossoms into something special (whichis what I expect), the $5-$10 range becomes a real possibility.
1) IntelGenx has a branded drug (ForFivo) which they s
uccessfully negotiated through to
FDA approval. Although ForFivo is not a “big” drug
, royalties and milestones from this
drug should end up covering IntelGenx’s $2million/y
ear operating burn; the industry
credibility that IntelGenx earned just from this ac
complishment should not be
underestimated, because few companies of IntelGenx’
s size are able to get drugs all the
way through the approval process.
2) By the end of 2013, IntelGenx will have successfull
y cleared the equivalent of Phase III
trials in the generic or 505b2 form of 4 branded dr
ugs that together register annual
sales of over $4.5billion. (What we don’t know is
how big a piece of that $4.5billion pie
will IntelGenx’s marketing partners be able to take
...)
3) IntelGenx has partnered with Par Pharmaceuticals—a
large and well-respected generic
drug company—for a generic form of thin-film Suboxo
ne, a drug which currently sells
over $1.5billion/year. With Par as a partner, it i
s reasonable to expect that IntelGenx
should share in sales somewhere in the $100million-
$300million range, allowing it to
generate EPS which should be in the $0.50/share-$1+
/share range from this drug alone
4) It is also a reasonable expectation that Par’s sati
sfaction with IntelGenx’s drug
formulation and development capabilities (proven in
the Suboxone project) means that
IntelGenx should be brought into more Par projects
in the near future. If we see that
happen, it will be fair to say that IntelGenx has b
ecome Par’s de facto partner for thin-
film drug delivery and development, and that IntelG
enx would be a natural takeout
candidate for Par.
5) With an approved drug on the market, proven deliver
y capabilities across 3 delivery
platforms (including thin-film strips), a clinical
pipeline of 7 drugs that includes 2 “post-
PhaseIII” drugs, IntelGenx should be a natural take
out candidate for any number of
generics manufacturers. (I believe that generics ma
nufacturers are being increasingly
drawn to the 505b2 pathway, and are likely to make
acquisitions of 505b2 companies,
as they seek to expand both their product offerings
and their profit margins.) IntelGenx
should also be a takeout candidate for specialty ph
arma companies, and perhaps even
BioDelivery Sciences, if the valuation gap remains
as ridiculous as it currently is.
Both Ram and I share an affinity for IntelGenx’s bu
siness model and proven abilities:
1) IntelGenx primarily uses the FDA’s 505b2 pathway to
approval, which minimizes toxicity
risk and efficacy risk (which is what kills almost
all biotech companies). Efficacy risk and
toxicity risk are minimized because IntelGenx is taking
existing drugs that sell hundreds
of millions (or billions) of dollars a year and mov
ing them onto delivery platforms which
make them better/faster/easier (like what Biovail d
id with Wellbutrin when Biovail
developed Wellbutrin XL).
2 )IntelGenx’s ability to bring a drug all the way thr
ough the FDA’s 505b2 pathway and to
launch an approved drug has been tested and proven.
There are few companies
with an FDA approved drug with a market cap under $
100million
; at US$0.54,
IntelGenx’s market cap is under US$
IGXT = FDA DECISION ON FEBRUARY 3 =500%++ Potential !!!
IGXT is one of the Best and Most Undervalued Gem in the Biotech Sector . Market Cap of $48 M for a Company with10 Drugs in Late Stage which all could be on the Market within 3 years is more than Ridiculous .
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 35 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $48 M
Cash: $6 M
Price:0.70
Burn-Rate : $2 M a year
Shares Out : 69 M ( 31 M shares are held by Investors )
Mega Product Pipeline
http://intelgenx.com/pipeline/chart.html
New Presentation
http://intelgenx.com/investors/presentations.html
Here is a Summary from he largest Shareholder of IGXT (he sees Tgt of $5-10) !!!
Frankly, my target (first stated in July, 2011) of realizing $3-$8/share from IntelGenx over the
life of the BIPES Fund has never seemed more reason able—the company has put in place more
than enough building blocks to see that kind of sto ck price by the of 2016, as it becomes
recognized as a world leader in the growing area of thin-film drug delivery and development. I
like the fact that my $3 low end corresponds to the already-existing 1-year target of Ram
Selvaraju, a well-respected and sophisticated Wall Street biotech analyst. If the PAR
partnership blossoms into something special (whichis what I expect), the $5-$10 range becomes a real possibility.
1) IntelGenx has a branded drug (ForFivo) which they s
uccessfully negotiated through to
FDA approval. Although ForFivo is not a “big” drug
, royalties and milestones from this
drug should end up covering IntelGenx’s $2million/y
ear operating burn; the industry
credibility that IntelGenx earned just from this ac
complishment should not be
underestimated, because few companies of IntelGenx’
s size are able to get drugs all the
way through the approval process.
2) By the end of 2013, IntelGenx will have successfull
y cleared the equivalent of Phase III
trials in the generic or 505b2 form of 4 branded dr
ugs that together register annual
sales of over $4.5billion. (What we don’t know is
how big a piece of that $4.5billion pie
will IntelGenx’s marketing partners be able to take
...)
3) IntelGenx has partnered with Par Pharmaceuticals—a
large and well-respected generic
drug company—for a generic form of thin-film Suboxo
ne, a drug which currently sells
over $1.5billion/year. With Par as a partner, it i
s reasonable to expect that IntelGenx
should share in sales somewhere in the $100million-
$300million range, allowing it to
generate EPS which should be in the $0.50/share-$1+
/share range from this drug alone
4) It is also a reasonable expectation that Par’s sati
sfaction with IntelGenx’s drug
formulation and development capabilities (proven in
the Suboxone project) means that
IntelGenx should be brought into more Par projects
in the near future. If we see that
happen, it will be fair to say that IntelGenx has b
ecome Par’s de facto partner for thin-
film drug delivery and development, and that IntelG
enx would be a natural takeout
candidate for Par.
5) With an approved drug on the market, proven deliver
y capabilities across 3 delivery
platforms (including thin-film strips), a clinical
pipeline of 7 drugs that includes 2 “post-
PhaseIII” drugs, IntelGenx should be a natural take
out candidate for any number of
generics manufacturers. (I believe that generics ma
nufacturers are being increasingly
drawn to the 505b2 pathway, and are likely to make
acquisitions of 505b2 companies,
as they seek to expand both their product offerings
and their profit margins.) IntelGenx
should also be a takeout candidate for specialty ph
arma companies, and perhaps even
BioDelivery Sciences, if the valuation gap remains
as ridiculous as it currently is.
Both Ram and I share an affinity for IntelGenx’s bu
siness model and proven abilities:
1) IntelGenx primarily uses the FDA’s 505b2 pathway to
approval, which minimizes toxicity
risk and efficacy risk (which is what kills almost
all biotech companies). Efficacy risk and
toxicity risk are minimized because IntelGenx is taking
existing drugs that sell hundreds
of millions (or billions) of dollars a year and mov
ing them onto delivery platforms which
make them better/faster/easier (like what Biovail d
id with Wellbutrin when Biovail
developed Wellbutrin XL).
2 )IntelGenx’s ability to bring a drug all the way thr
ough the FDA’s 505b2 pathway and to
launch an approved drug has been tested and proven.
There are few companies
with an FDA approved drug with a market cap under $
100million
; at US$0.54,
IntelGenx’s market cap is under US$
IGXT = FDA DECISION ON FEBRUARY 3 =500%++ Potential !!!
IGXT is one of the Best and Most Undervalued Gem in the Biotech Sector . Market Cap of $48 M for a Company with10 Drugs in Late Stage which all could be on the Market within 3 years is more than Ridiculous .
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 35 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $48 M
Cash: $6 M
Price:0.70
Burn-Rate : $2 M a year
Shares Out : 69 M ( 31 M shares are held by Investors )
Mega Product Pipeline
http://intelgenx.com/pipeline/chart.html
New Presentation
http://intelgenx.com/investors/presentations.html
Here is a Summary from he largest Shareholder of IGXT (he sees Tgt of $5-10) !!!
Frankly, my target (first stated in July, 2011) of realizing $3-$8/share from IntelGenx over the
life of the BIPES Fund has never seemed more reason able—the company has put in place more
than enough building blocks to see that kind of sto ck price by the of 2016, as it becomes
recognized as a world leader in the growing area of thin-film drug delivery and development. I
like the fact that my $3 low end corresponds to the already-existing 1-year target of Ram
Selvaraju, a well-respected and sophisticated Wall Street biotech analyst. If the PAR
partnership blossoms into something special (whichis what I expect), the $5-$10 range becomes a real possibility.
1) IntelGenx has a branded drug (ForFivo) which they s
uccessfully negotiated through to
FDA approval. Although ForFivo is not a “big” drug
, royalties and milestones from this
drug should end up covering IntelGenx’s $2million/y
ear operating burn; the industry
credibility that IntelGenx earned just from this ac
complishment should not be
underestimated, because few companies of IntelGenx’
s size are able to get drugs all the
way through the approval process.
2) By the end of 2013, IntelGenx will have successfull
y cleared the equivalent of Phase III
trials in the generic or 505b2 form of 4 branded dr
ugs that together register annual
sales of over $4.5billion. (What we don’t know is
how big a piece of that $4.5billion pie
will IntelGenx’s marketing partners be able to take
...)
3) IntelGenx has partnered with Par Pharmaceuticals—a
large and well-respected generic
drug company—for a generic form of thin-film Suboxo
ne, a drug which currently sells
over $1.5billion/year. With Par as a partner, it i
s reasonable to expect that IntelGenx
should share in sales somewhere in the $100million-
$300million range, allowing it to
generate EPS which should be in the $0.50/share-$1+
/share range from this drug alone
4) It is also a reasonable expectation that Par’s sati
sfaction with IntelGenx’s drug
formulation and development capabilities (proven in
the Suboxone project) means that
IntelGenx should be brought into more Par projects
in the near future. If we see that
happen, it will be fair to say that IntelGenx has b
ecome Par’s de facto partner for thin-
film drug delivery and development, and that IntelG
enx would be a natural takeout
candidate for Par.
5) With an approved drug on the market, proven deliver
y capabilities across 3 delivery
platforms (including thin-film strips), a clinical
pipeline of 7 drugs that includes 2 “post-
PhaseIII” drugs, IntelGenx should be a natural take
out candidate for any number of
generics manufacturers. (I believe that generics ma
nufacturers are being increasingly
drawn to the 505b2 pathway, and are likely to make
acquisitions of 505b2 companies,
as they seek to expand both their product offerings
and their profit margins.) IntelGenx
should also be a takeout candidate for specialty ph
arma companies, and perhaps even
BioDelivery Sciences, if the valuation gap remains
as ridiculous as it currently is.
Both Ram and I share an affinity for IntelGenx’s bu
siness model and proven abilities:
1) IntelGenx primarily uses the FDA’s 505b2 pathway to
approval, which minimizes toxicity
risk and efficacy risk (which is what kills almost
all biotech companies). Efficacy risk and
toxicity risk are minimized because IntelGenx is taking
existing drugs that sell hundreds
of millions (or billions) of dollars a year and mov
ing them onto delivery platforms which
make them better/faster/easier (like what Biovail d
id with Wellbutrin when Biovail
developed Wellbutrin XL).
2 )IntelGenx’s ability to bring a drug all the way thr
ough the FDA’s 505b2 pathway and to
launch an approved drug has been tested and proven.
There are few companies
with an FDA approved drug with a market cap under $
100million
; at US$0.54,
IntelGenx’s market cap is under US$
keep dreaming ,this stock will never go below 0.60 so close to FDA decision . This upmove is supported by the highest volume in history of this company and thats why it will not go down only if FDA rejects which will not happen .
RDHL.TA is green despite the offering because RDHL is still brutally undervalued
http://finance.yahoo.com/q?s=RDHL.TA&ql=0
3.9 NIS (Shekel) is around $1.12 per share (10,458,740 M ) on TASE
they selling these shares in Isreal .The Share outstanding is now around 74 million in Isreal (TASE) and 7.4 M in USA (Nasdaq) based on ADS which means 10 shares for 1 .
You did a big mistake selling close to FDA decision but good luck anyway to you .
It will make big jumps once it breaks the $1 Mark just have patience . Payday is very close
Good Times Ahead for IGXT
I smell big money here hehe
Who is buying this Bankruptcy SCAM ? Be careful guys
AEZS ..Market Cap $50 ..Cash $40 M and FDA approval by mid 2014
1 Marketed Drug /1x Drug under review by FDA / 8x Drugs in P2 / 1x Drug in P3 //
A fantastic buying opportunity guys
XNY exploding i hope you guys bought some
XNY = a UNDISCOVERED LOW FLOAT MONSTER GEM
XNY (MC $74 M) Price $1.30 / $3.12 Cash Per Share / Revenue $220 M / Float 16 M / P/E 3
Rexista which is in Phase 3 alone is still worth more than current market cap of around $125 Mil .
Near term risk is that the stock is highly overbought (RSI 94) and a possible share offering but i hope that they exercised the warrants during this run .
Profitability now within 1Q 2014 this is super big news for IPCI .
Buyout or FDA approval lets see which one it is .
OXGN (MC $7 M) Cash $8.8 M / FLOAT 2 M / 2 Drugs in P3 =TGT $10+
OXGN ..Float 2 M .. Trading below cash Market Cap$7 M ..Cash $8.8 M
they have a full pipeline of cancer drugs
AEZS starts runnningggg guys
AEZS ..close to a major breakout guys
Price $1.39
Near term Tgt $2-2.50
Aezs is a real Big Opportunity which you can buy currently at All Time Low ,the only reason for the very low price was just a Share offering a few weeks ago .
AEZS has already a Drug on the Market which is partnered with pharma giant Merck (MRK) , the annual revenue for the product is around $70 M thats almost two times higher than current Market Cap .
AEZS has another Drug awaiting FDA approval and muliple Cancer Drugs in Late Stage some of them a potential Blockbusters .
I think AEZS has the potential for runup to minimum to $4-5 before FDA decision in Mid 2014 . GL
AEterna Zentaris (AEZS)
Market Cap: $43 M
Cash: $24 M
Price: $1.35
Shares Out: 32 M
Annual Revenue :$ 70 M
MEGA Pipeline
http://www.aezsinc.com/en/page.php?p=20
New Presentation
http://www.aezsinc.com/pdfdyn/AEZS_Presentation_November_8_2013-FINAL%20Public.pdf
Fact Sheet
http://www.aezsinc.com/pdfdyn/FACT-SHEET-ENGLISH-August-2013.pdf
Macimorelin Acetate (AEZS-130)
Diagnostic in adult growth hormonedeficiency (endocrinology) under review by FDA
Product ..Zoptarelin Doxorubicin (AEZS-108)
Endometrial cancer in Phase 3
Tripl-negative breast cancer In Phase 2
Castration-and taxane-resistant prostate cancer in Phase 2
Refractory bladder cancer in Phase 2
Ovarian cancer (completed) in Phase 2
Product ..Ozarelix :
Prostate cancer in Phase 2
Product ..Macimorelin Acetate (AEZS-130)
Therapeutic in cancer cachexia in Phase 2
Product ..Perifosine
Multiple cancers in Phase 2
AEZS .A great Buying Opp
Check it out guys and buy this significantly underpriced stock atthe bottom if you want to make money .GLTA
This one is definitely one of the cheapest FDA Plays out there .
Ticker: AEZS
Market Cap: $42 M
Cash: $25 M
Shares Out: 32 M
Aeterna Zentaris Inc. (AEZS) today announced that it has submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency ("AGHD"), with accuracy comparable to available intravenous and intramuscular testing procedures.
David Dodd, President and CEO of Aeterna Zentaris, commented, "The submission of the NDA to the FDA is another major milestone in our strategy to bring macimorelin acetate to market as the first approved oral product for AGHD evaluation. We are also looking at potential expansion into traumatic brain injury victims and pediatrics which would represent significant growth opportunities for the Company. Finally, I would like to congratulate and thank all those involved in our drug development and regulatory affairs departments for this exciting accomplishment."
IG = A REAL Undiscovered Goldmine with Monster Upside Potential .. GLTA !!
Summary :
1) Laughable Market Cap of $99 M
2) Cash for 12 Months ....... Profitability before Year End
3) 4x Products launched in USA since December 2012
4) 13x Products under review by FDA many of these will get FDA approval within 12 Months
5) Another 1x ANDA filings coming before year end
6) 72% of all Shares Outstanding held by Insiders & Institutions and still buying more
7) Small Float of only ~11 Million Shares
I think targets of $8-12 within 1-2 years is more realistic than Roth Capitals $3.50 .
Ticker ( IG )
Market Cap : $99 M
Cash : $2.3 M
Price : $2.30
Shares Out : 43 M .....(31 Million Shares held by Big Investors)
Float : 11 M
IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “Our team has done a tremendous job this quarter. This quarter marks the fifth consecutive quarter of top line growth. Our net loss is rapidly approaching break even for the first time at IGI in over twenty-two quarters. We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013.” Mr. Grenfell-Gardner continued, “Our research and development team has now filed four ANDAs in 2013, which brings our total filings pending with the US FDA to twelve. Based on current IMS data, the addressable market for our pipeline of twelve ANDAs, pending approval at the US FDA is estimated at over $300 million. Our team is committed to our plan to file at least six ANDAs in 2013. We believe we are on track to at least double our 2012 total revenue and achieve profitability in 2013.”
HIHO next low float
HIHO (MC $8 M)Price: $2.38 / Book Value $3.22 & Profitable/ Pays Dividend / Float 2.2 M
NURO trading below cash and has a big product approved . This one will explode like a nuclear bomb guys .GL
---
“SENSUS is the first and only transcutaneous electrical nerve stimulator that specifically includes use during sleep within its 510(k) indications,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “We believe that growing recognition of the inter-relationship between chronic pain, such as painful diabetic neuropathy, and sleep disturbances is clinically important and represents a unique market position for SENSUS. We will build on this expanded indication by launching a series of novel sleep enabling features for SENSUS over the next 12 months.”
The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy and similar peripheral neuropathies.It is the only transcutaneous electrical nerve stimulator designed specifically for people with diabetes and chronic pain. The most common cause of such pain in people with diabetes is painful diabetic neuropathy (PDN), which affects up to 5 million people in the US alone.
The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States